A Cascade‐Targeted Enzyme‐Instructed Peptide Self‐Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death
Small Methods · 2023
DOI: 10.1002/smtd.202201416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2023. Verfasst von Limin Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, 300071, P. R. China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunogenic cell death (ICD) approaches by encumbering mitochondrial functions provide great promise for the treatment of malignant tumors, but these kinds of ICD strategies are still in their infancy. Here, one multifunctional drug‐loaded, cascade‐targeted, and enzyme‐instructed self‐assembling peptide nanomedicine ( Comp. 4 ) for ICD‐based cancer therapy is constructed. Comp. 4 consists of 1) lonidamine (LND) that specifically interferes with mitochondrial functions; 2) a programmed death ligand 1 (PD‐L1) binding peptide sequence (NTYYEDQG) and a mitochondria‐specific motif (triphenylphosphonium, TPP) that can sequentially control the cell membrane and mitochondria targeting capacities, respectively; and 3) a ‐G D F D Fp D Y‐ assembly core to in situ organize peptide assemblies responsive to alkaline phosphatase (ALP). Comp. 4 demonstrates noticeable structural and morphological transformations in the presence of ALP and produces peptide assemblies in mouse colon cancer cells (CT26) with high expressions of both ALP and PD‐L1. Moreover, the presence of PD‐L1‐ and mitochondria‐specific motifs can assist Comp. 4 for effective endocytosis and endosomal escape, forming peptide assemblies and delivering LND into mitochondria. Consequently, Comp. 4 shows superior capacities to in vivo induce abundant mitochondrial oxidative stress, provoke robust ICD responses, and produce an immunogenic tumor microenvironment, successfully inhibiting CT26 tumor growth by eliciting a systemic ICD‐based antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, 300071, P. R. China.
- Key Laboratory of Bioactive Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
- Department of Urology, Tianjin First Central Hospital, Tianjin, 300192, P. R. China.
- School of Medicine, Nankai University, Tianjin, 300071, P. R. China.
ORCID-Profile: Zhimou Yang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Xie, L., Ding, Y., Zhang, X., Zhang, Z., Zeng, S., Wang, L., Yang, Z., Liu, Q., & Hu, Z. W. (2023). A Cascade‐Targeted Enzyme‐Instructed Peptide Self‐Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death. Small Methods. https://doi.org/10.1002/smtd.202201416
Vancouver
Xie L, Ding Y, Zhang X, Zhang Z, Zeng S, Wang L, et al. A Cascade‐Targeted Enzyme‐Instructed Peptide Self‐Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death. Small Methods. 2023. doi:10.1002/smtd.202201416
BibTeX
@article{Xie2023,
author = {Xie, Limin and Ding, Yinghao and Zhang, Xiangyang and Zhang, Zhenghao and Zeng, Sheng and Wang, Ling and Yang, Zhimou and Liu, Qian and Hu, Zhi-Wen},
title = {A Cascade‐Targeted Enzyme‐Instructed Peptide Self‐Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death},
journal = {Small Methods},
year = {2023},
doi = {10.1002/smtd.202201416}
}
EUVIMED